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Purpose: The study aimed to examine attitudes of individuals diagnosed with sarcoma and their family members
towards genetics, genomic research and incidental information arising as a result of participating in genetic
research.
Methods: A questionnaire was administered to 1200 individuals from the International Sarcoma Kindred Study
(ISKS). Respondents were divided into three groups: individuals affected with sarcoma (probands), their spouses and
family members.
Results: Approximately half of all research participants felt positively towards new discoveries in human genetics.
Overall, more were positive in their attitudes towards genetic testing for inherited conditions (60%) but family
members were less so. Older participants reported more highly positive attitudes more often than younger
participants. Males were less likely to feel positive about new genetic discoveries and more likely to believe they
could modify genetic risk by altering lifestyle factors. Almost all ISKS participants believed participants would like to
be given ancillary information arising as a result of participating in genetic research.
Conclusions: The only difference between the study groups was the decreased likelihood of family members
being highly positive about genetic testing. This may be important if predictive testing for sarcoma becomes
available. Generally ISKS research participants supported the notion of returning incidental genetic information to
research participants.Introduction
The evolution of new genomic technologies such as
chromosomal microarray analysis and massively parallel
sequencing of targeted regions and potentially the whole
exome or genome, can result in the identification of in-
cidental genetic information, in both clinical practice
and medical research. This information has potential
relevance to individuals and their families. Extensive dis-
cussion amongst researchers, health professionals, law-
yers and bioethicists continues in an attempt to resolve
the myriad of dilemmas including balancing the medical,
ethical, psychosocial and social implications of new gen-
omic technologies [1-4]* Correspondence: mary-anne.young@petermac.org
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reproduction in any medium, provided the orReaching consensus about the innumerable complex-
ities surrounding this issue creates enormous challenges.
In the research setting the issues include considering the
appropriateness of returning certain findings; how to ob-
tain the funding required to return results so that the re-
search is not crippled; balanced against avoiding undue
distress to research participants and appropriate clinical
follow up. The culmination of a two year project funded
by the National Institutes of Health has resulted in pub-
lished recommendations to assist biobanks and archived
data sets in managing incidental information and gen-
omic research results [5,6].
It is equally important that the discussion include the
contribution and opinions of research participants and
the general public. There is mounting evidence showing
they are interested in receiving incidental information
[7-11]. Previous research has shown that individuals’Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sponse to genetic information, although greater know-
ledge does not lead to unequivocal acceptance of genetic
technology and testing [12-16].
Sarcomas are malignant tumours of connective tissue.
They are rare although contribute disproportionately to
cancer burden as they often affect the young, treatment
is costly and prolonged, and morbidity and mortality
high [17,18]. Genetic factors appear important in sar-
coma, although have not been well studied. The ISKS, a
clinic-based study, recruits individuals with sarcoma ag-
nostic to family history, as well as their partners and
genetic relatives creating a resource for future research
into the genetic factors contributing to the hereditary
risk of developing sarcoma [19,20].
We sought to provide additional data to the discussion
about incidental information by conducting a study with
individuals affected by adult-onset sarcoma (probands),
their spouses and family members, all of whom were
participants in the ISKS.
Our aim in this exploratory study was to examine and
compare the attitudes towards and opinions about gen-




Individuals with a histologically confirmed sarcoma
were recruited through key sarcoma clinics through-
out Australia. If the proband was diagnosed <45 yrs
or was diagnosed ≥45 yrs and had a significant family
history of cancer, genetic relatives were additionally
recruited. Age matched (±5 yrs) comparison groups
were also recruited. All participants were asked to
complete a broad baseline questionnaire and provide
biospecimens.
Survey development
We developed a discrete set of questions to include in
the larger baseline questionnaire administered to all
study participants. The questions on attitudes to genetic
testing and genomic research were developed using the
UK Human Genetics Commission 2001 report into Pub-
lic Attitudes to Human Genetic Information [21] and
study specific questions were designed to examine atti-
tudes to incidental information arising from participa-
tion in research.
The questions asked about:
1. Beliefs in the genetic versus environmental
contribution to aspects of health and well-being.
2. Feelings towards new genetic discoveries.
3. Attitudes towards genetic testing for inherited
conditions.4. Attitudes towards the possibility of “incidental
findings” as a result of participating in genetic
research.
Questions about new genetic discoveries covered six
items on a seven point Likert scale (bored/excited, valu-
able/worthless, uninterested/interested, indifferent/pas-
sionate, don’t care/care and important/unimportant).
Scores for the six items were averaged, and participants
were categorised as being ‘highly positive’ (mean ≥ 6) or
‘less positive’ (≤ 6).
The questions about genetic testing for inherited con-
ditions covered five domains on a seven point Likert
scale (favourable/unfavourable, calm/anxious, trusting/
sceptical, good idea/bad idea and acceptable/unaccept-
able) with participants categorised as being ‘highly posi-
tive’ or ‘less positive’ on the basis of their mean scores as
above.
The study received ethical approval from the Human
Research Ethics Committee at the main study site, Peter
MacCallum Cancer Centre, Victoria, Australia as well as
all seven other recruiting sites throughout Australia.
Data collection
Data were collected from July 2009 to May 2012. The
questionnaire relating to this study was self-administered
at the time of recruitment to ISKS.
Data analysis
The data were analysed in STATA (version 12.1), with
the participant category (proband, family member or
spouse/partner) being the main exposure of interest.
The distributions of all covariates and outcomes were
examined using Chi square tests for heterogeneity for
normally distributed, categorical data. Multivariable lo-
gistic regression (for binary outcomes) enabled adjust-
ment of the outcomes of interest for potential
confounders or partial intermediates described as ex-
planatory factors. These included age, gender, education,
and country of birth.
Clustering within families was accounted for by fitting
Generalised Estimating Equation regression models.
Results
Table 1 shows the participant characteristics in terms of
age, gender, relationship status, education and country
of birth.
Forty four percent of the total sample was adult pro-
bands i.e. with sarcoma, with nineteen percent having
had two or more primary malignancies. Fifty percent
had been diagnosed with sarcoma within 12 months of
participating in the study.
There were no marked differences between the three
categories of participants in age group frequencies,
Table 1 Participant characteristics
All Proband Family Spouse p-value
n=1200 n=524 n=514 n=162
Age at study 0.25
18 to 39 years, n (%) 332 (28%) 159 (30%) 137 (27%) 36 (22%)
40 to 60 years, n (%) 472 (39%) 192 (37%) 210 (41%) 70 (43%)
61 years & older, n (%) 396 (33%) 173 (33%) 167 (32%) 56 (35%)
Female, n (%) 638 (53%) 241 (46%) 303 (59%) 94 (58%)
Partnered, n (%) 859 (72%) 343 (66%) 362 (71%) -
Highest education completed 0.08
High School, n (%) 268 (22%) 110 (21%) 129 (25%) 29 (18%)
University/Vocational, n (%) 603 (50%) 260 (50%) 262 (51%) 81 (50%)
Country of birth 0.005
Australia, n (%) 921 (77%) 382 (73%) 418 (81%) 121 (75%)
Cancer <0.001
Yes, n (%) 624 (52%) - 96 (19%) 4 (2%)
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ences in terms of gender (Chi square = 18.97, p = <0.001)
with almost 60% of spouses and family members being
female and less than 50% of the probands female. There
were also differences in terms of country of birth (COB),
with 73% of probands born in Australia compared to
81% of family members (Chi square = 10.76, p < 0.005).Beliefs in the genetic versus environmental contribution
to aspects of health and well-being
There were no significant differences observed between
probands, spouses and family members in beliefs in an
inherited contribution to the characteristics or health
condition (Figure 1). A greater number of participants in
all groups assigned greater emphasis to the genetic con-
tribution to breast cancer as compared to bowel cancer.Feelings about genetic discoveries
The proportion of probands, family members and
spouses that felt highly positive about new genetic dis-
coveries was 53%, 49.2% and 57.4% respectively. After
adjusting for age, gender, education, country of birth
and genetic beliefs, there was no difference in the odds
of a family member or spouse having different feelings
from the proband (Table 2). Older participants
(≥61 years), were more likely to feel highly positive about
genetic discoveries when compared with younger partici-
pants (AdjOR 1.47, 95% CI: (1.06-2.05)) and males had a
lower odds of feeling highly positive compared to fe-
males (AdjOR 0.66, 95% CI: (0.52-0.82)). Individuals
who had a university education had an increased odds of
feeling highly positive compared to those of lower edu-
cation (AdjOR 1.45, 95% CI: (1.07-1.97)).Attitudes towards genetic testing
The proportion of probands, family members and spouses
that felt highly positive about genetic testing for inherited
conditions was 66.8%, 59.7% and 61.7% respectively. All
groups were asked about their attitudes to genetic testing
for inherited conditions (in general). Compared to pro-
bands, family members had a lower odds of being highly
positive (AdjOR 0.69, 95% CI: (0.53-0.88)) (Table 3).
Older participants (≥61 yrs) reported significantly higher
positive attitudes towards genetic testing than younger
participants (AdjOR 2.06, 95% CI:(1.50-2.84)).
Beliefs about the ability to modify inherited risk by
lifestyle factors
Forty percent of probands, 44% of spouses and 38% of
family members believed it was possible to alter an
inherited risk by modifying lifestyle factors e.g. eating
better, having more exercise or following a special health
program (Table 4). There were no differences in partici-
pant category although males were more likely to believe
risk could be altered (AdjOR 1.64, 95% CI: (1.28-2.08))
as were individuals who had tertiary education (AdjOR
1.39, 95% CI: (1.01-1.91)).
Opinions and attitudes towards incidental information
arising as a result of research
The questionnaire used four hypothetical scenarios to
determine what conditions people would like to be in-
formed about when incidental information arises as a re-
sult of participating in research. These scenarios were
(1) risk for a disease caused by a single gene for which
there is no prevention e.g. inherited blindness; (2) risk
for a disease caused by one gene for which there is evi-
dence that prevention such as screening or treatment





















Figure 1 Proportion of probands, family members and spouses who indicated characteristic was inherited.
Table 2 Feelings about genetic discoveries
Feelings about genetic discoveries
Bivariable analysis Multivariable analysis
Variable Category OR 95% CI p Adj OR 95% CI p
Participant Proband Ref Ref Ref Ref Ref Ref
Family member 0.86 0.67-1.09 0.22 0.80 0.62-1.05 0.11
Spouse 1.19 0.84-1.70 0.33 1.15 0.81-1.63 0.45
Age at study 18 to 39 years Ref Ref Ref Ref Ref Ref
40 to 60 years 1.07 0.81-1.42 0.63 1.04 0.77-1.41 0.79
61 years and older 1.41 1.05-1.89 0.02 1.47 1.06-2.05 0.02
Gender Female Ref Ref Ref Ref Ref Ref
Male 0.67 0.54-0.84 0.00 0.66 0.52-0.82 <0.001
Highest education Primary School Ref Ref Ref Ref Ref Ref
High School 1.016 0.74-1.40 0.92 1.20 0.85-1.68 0.30
University/Vocational 1.311 1.00-1.72 0.05 1.45 1.07-1.97 0.02
Country of birth Australia/NZ Ref Ref Ref Ref Ref Ref
Other 1.350 1.03-1.77 0.03 1.21 0.89-1.65 0.22
Logistic regression analysis. 0 = Less positive, 1 = Highly positive.
Multivariable analysis adjusted for age, gender, education, COB, genetic beliefs.
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Table 3 Attitudes towards genetic testing
Attitudes towards genetic testing
Bivariable analysis Multivariable analysis
Variable Category OR 95% CI p Adj OR 95% CI p
Participant Proband Ref Ref Ref Ref Ref Ref
Family member 0.74 0.57-0.95 0.02 0.69 0.53-0.88 <0.003
Spouse 0.80 0.56-1.16 0.24 0.78 0.54-1.12 0.18
Age at study 18 to 39 years Ref Ref Ref Ref Ref Ref
40 to 60 years 1.15 0.86-1.53 0.34 1.22 0.91-1.65 0.19
61 years and older 1.83 1.34-2.48 <0.001 2.06 1.50-2.84 <0.001
Gender Female Ref Ref Ref Ref Ref Ref
Male 0.85 0.67-1.08 0.18 0.82 0.64-1.04 0.10
Highest education Primary School Ref Ref Ref Ref Ref Ref
High School 1.01 0.73-1.15 0.94 1.32 0.92-1.91 0.14
University/Vocational 0.99 0.75-1.31 0.94 1.22 0.88-1.68 0.23
Country of birth Australia/NZ Ref Ref Ref Ref Ref Ref
Other 0.87 0.66-1.15 0.32 0.75 0.55-1.03 0.07
Logistic regression analysis. 0 = Less positive, 1 = Highly positive.
Multivariable analysis adjusted for age, gender, education, COB, genetic beliefs.
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for a disease caused by many genes which can have a
major impact on health for which there is specified
treatment or lifestyle modification such as improving
diet, stopping smoking, or increasing exercise which can
modify the risk e.g. heart disease; (4) risk for a disease
caused by many genes which usually have a lower im-
pact on health for which there is treatment as well as
lifestyle changes which can modify the risk e.g. asthma.Table 4 Beliefs about altering inherited risk by modifying life
Beliefs about alte
Bivariable analys
Variable Category OR 95%
Participant Proband Ref Ref
Family member 0.91 0.71-
Spouse 1.19 0.84-
Age at study 18 to 39 years Ref Ref
40 to 60 years 0.93 0.70-
61 years and older 0.74 0.55-
Gender Female Ref Ref
Male 1.61 1.28-
Highest education Primary School Ref Ref
High School 1.29 0.92-
University/Vocational 1.46 1.11-
Country of birth Australia/NZ Ref Ref
Other 1.15 0.88-
Logistic regression analysis. 0 = Not possible to alter risk, 1 = Possible to alter risk.
Multivariable analysis adjusted for age, gender, education, COB, genetic beliefs.Table 5 shows that almost all ISKS participants
responded saying they believed that people taking part
in genetic research would like to be informed about inci-
dental findings for which there is prevention and/or
treatment. Overall, fewer participants felt people would
like to be informed about a single gene disorder for
which there is no prevention with a higher proportion of
spouses (76%) than probands (67%) and family members
(66%) responding positively to this. Adjusting for age,style factors
ring disease risk
is Multivariable analysis
CI p Adj OR 95% CI p
Ref Ref Ref Ref
1.17 0.47 0.98 0.74-1.30 0.85
1.70 0.33 1.29 0.90-1.84 0.17
Ref Ref Ref Ref
1.24 0.64 0.95 0.72-1.27 0.75
1.00 0.05 0.78 0.56-1.08 0.14
Ref Ref Ref Ref
2.04 <0.001 1.64 1.28-2.08 <0.001
Ref Ref Ref Ref
1.81 0.13 1.21 0.84-1.73 0.30
1.94 0.01 1.39 1.01-1.91 0.04
Ref Ref Ref Ref
1.51 0.32 1.15 0.83-1.59 0.41
Table 5 Participant opinions and attitudes towards genetic testing and research: proportion of each participant group
responding to the different scenarios
When people take part in genetic research, I think they would like to be
informed about:
All Proband Family Spouse P-value
n=1200 n=524 n=514 n=162
Known genetic conditions caused by one gene, for which there is no prevention 68% 67% 66% 76% 0.05
Known genetic conditions caused by one gene, for which there is prevention
or treatment that can change the risk
94% 94% 93% 95% 0.43
Known genetic conditions caused by many genes, which can have a major
impact on health, for which there is treatment as well as lifestyle factors
which can modify the risk
93% 93% 93% 96% 0.70
Known genetic conditions caused by many genes, which usually have a lower
impact on health, for which there is treatment as well as lifestyle factors which
can modify the risk
90% 89% 89% 92% 0.83
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significance (AdjOR 1.52, 95% CI:(1.02-2.26)).
Discussion
This study about ISKS participants’ attitudes towards
genomics and incidental information generated through
research brings the consumer viewpoint to the discus-
sion about the numerous complex issues raised by the
use of new genetic technology. Our results showed that
approximately half of the ISKS participants, including
individuals affected with sarcoma, their spouses and
family members felt positively towards new discoveries
in human genetics. Their attitudes towards genetic test-
ing for inherited conditions were slightly more positive.
We did not measure knowledge, although previous re-
search has shown an association between knowledge
about genes and attitudes towards genetic tests with
higher levels of knowledge being positively associated
with acceptance of biotechnology, attitudes to science
and attitudes towards genetic testing [12,22,23]. ISKS
participants, though not necessarily reflective of the gen-
eral population, are representative of those involved in
disease associated research.
As shown in Figure 1 there was no significant difference
between the groups concerning their beliefs about the
genetic contribution to aspects of health and well-being
(see Figure 1). Rather, there was remarkable consistency
amongst the three groups. Of interest was the number of
participants who assigned greater emphasis to the genetic
contribution to breast cancer as compared to bowel can-
cer despite the heritable component of bowel cancer being
up to 30% [24]. This highlights the need for continuing
education to improve the public’s knowledge and genetic
literacy about genetics and genetic testing. The best pos-
sible use of genetic information to improve health de-
pends on this. Education should include information
about the social and ethical issues associated with the de-
velopment of genomic technology and genetic testing.
This will ensure those faced with the choice of accessing
and utilising genetic information have the necessarybackground knowledge for informed decision making.
Moreover, it will mean the public can meaningfully con-
tribute to the debate about emerging genetic technologies,
cognisant about all the issues. Education must also be in-
clusive of health professionals, particularly in primary
care, as they will be increasingly likely to play a role in the
delivery of complex genetic information to patients.
Link between knowledge and attitudes to genetics
It has been suggested that better genetic knowledge results
in a greater appreciation and support of science. Accord-
ingly, a lack of knowledge may explain the reservations and
fears some of the public express when asked about genetic
technologies [25] and the findings in this study that only
half felt positively about new genetic discoveries. Whilst
there is debate about the role of knowledge and its relation-
ship to the acceptance of gene technology some studies
have identified knowledge as a factor possibly influencing
the public’s attitudes and hence their support to science,
biotechnology and genetics, which can be either positive or
negative [26].
Knowledge is comprised of objective knowledge (i.e.
what people actually know), and subjective knowledge
(i.e. what people perceive they know). Objective know-
ledge is derived from diverse sources and may not al-
ways be correct. For example, films and books with
important genetic themes have often been critiqued due
to their inaccuracy or for distortion of the scientific facts
[27] although their influence cannot be underestimated
in influencing the general public’s understanding and
perception of genetics.
The relationship between knowledge and attitudes is not
clear and other factors like emotions and previous experi-
ence with genetic disease have also been shown to influence
perception. This is known as experiential knowledge
[25,26]. A recent study examining factors that influence
people’s acceptance of gene technology showed that the ex-
periential system which is based on affect, narratives, asso-
ciations and imageries is more influential in lay people’s
perceptions of genetic technology than the analytical
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dence [26]. Experiential knowledge may explain the finding
that probands in the ISKS cohort were more positive in
their attitudes towards genetic testing than family members
(see Table 3). Probands have been diagnosed and treated
for sarcoma, thus could be considered to have intimate ex-
periential knowledge. They may also have had some prior
knowledge about the role of genetics in sarcoma through
discussion with their treating doctors and/or as part of the
consent process to the study. As well, they may believe they
could have personally benefitted from genetic information
in regards to earlier diagnosis and personalised medical
treatment if it existed. This raises the tantalising nature of
genetic information and the public’s tendency to overrate
its power to predict and/or prevent disease [28].
Individuals with higher levels of education have been
shown to have more positive attitudes towards genetic
technology [23,26,29]. Higher education is theoretically as-
sociated with greater knowledge and it is possible that this
group may be more accepting of genetic technology. Edu-
cation was a significant factor that influenced ISKS partici-
pant’s feelings about genetic discoveries and beliefs about
the ability to modify inherited risk. Individuals who had a
university or vocational education were more likely to feel
positive about new genetic discoveries (Table 3) and were
more likely to believe in the ability to modify genetic risk
(Table 4).
Influence of sociodemographic variables
As stated above, education was an important confounder
in this study as was age, particularly how participants
felt about new genetic discoveries and attitudes towards
genetic testing with older participants reporting higher
positive attitudes as compared to younger participants
(Table 3). Our finding could be explained by the fact that
older people in our study may have had greater concern
about the implications to their own offspring and there-
fore feel more hopeful about new medical developments,
including genetics. This finding is different to a popula-
tion based Finnish study where older participants were
more likely to state they ‘did not know’ when asked
about their attitudes towards genetic testing [12].
Males in the ISKS cohort were less likely to feel positive
about new genetic discoveries and their scores suggested a
stronger belief that inherited risk could be altered by modi-
fying lifestyle factors when compared to females. This find-
ing about males feeling less positive is in contrast with
previous research which has shown that men tend to assess
genetic technology more positively than women [26]. The
higher expression of this belief by males in the ISKS cohort
could be explained by an active coping style or male social-
isation patterns [30]. Men are generally not active health
seekers although as they have a more active coping style
they want to do something [31]. These finding must beconsidered in the light of previous research which has dem-
onstrated that intentions or attitudes may not always pre-
dict behaviour [32]. In addition, although individuals state
they wish to use genetic information to modify risk, studies
of direct to consumer genetic testing have so far shown it
does not lead to changes in behaviour relating to exercise
and diet, or lead to further screening and preventative ac-
tion [33,34].
Incidental findings
The majority of ISKS participants thought research par-
ticipants would like to be informed about incidental
findings arising as a result of participating in medical re-
search. This finding supports mounting evidence in the
literature that individuals are interested in receiving inci-
dental information for reasons not only related to clin-
ical utility but also personal utility, autonomy and
choice. This includes gaining a sense of personal control
and helping to plan for the future [7,9,10,35,36].
A novel finding of this study is that less ISKS partici-
pants thought people would like to be informed about
monogenic conditions where there is no prevention as
compared to monogenic conditions where there is
existing prevention or treatment or polygenic disorders.
Importantly, there are few proven risk modification
strategies for the most commonly recognised sarcoma
predisposition syndrome, Li-Fraumeni syndrome (LFS).
The lifetime risk for cancer in classic LFS approaches
100% for females [37]. The desire to know and not know
about unmodifiable risk is therefore important to further
research into the genetic causes of sarcomas, and sup-
ports the notion of individual choice when making deci-
sions about what findings participants receive. Lay
individuals, in a recent study exploring attitudes about
the disclosure of incidental information, expressed the
importance of pre-test discussions to establish partici-
pant views around the type of information they would
like to receive and avoid unanticipated results. They also
stated they did not want health professionals to make
decisions on their behalf [35]. The results from our
study suggest that the public can be discerning when
presented with choices around the type of information
they wish to receive or not receive.
Information participants choose to receive may not be
the same as what clinicians consider is important to re-
turn. The National Institutes of Health [6] use the term
‘actionability’ to assist in determining whether or not to
return information. They define actionability from the
perspective of the individual facing risk and potential
disease. Actionability can mean different things to differ-
ent parties; including researchers, clinicians, human re-
search ethics committees, research participants and the
public. Whilst clinicians might consider clinical utility
and ability to interpret and communicate such
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information valuable for reasons including personal util-
ity [8,38]. Therefore, it is essential research participants
are involved in the decision about what information they
wish to receive when they consent to participate in re-
search. A recent study found that 75% of potential re-
search participants stated they would be less likely to
participate in research if incidental findings were not
returned indicating some participants may see returning
information as a proviso of enrolment into research [39].
The strength of this study is the large sample size and
the broad representation from multiple clinics across
Australia. A limitation to this research is that the ques-
tions were general and knowledge was not assessed.
Therefore the association between knowledge and atti-
tudes towards incidental findings is not able to be
assessed here and is worthwhile exploring in further
research.
A further limitation is that this research is based on
hypothetical scenarios and responses from individuals
when presented with a hypothetical scenario are not al-
ways consistent with future individual behaviour [32].
Conclusion
In conclusion, we have shown that at least half of ISKS par-
ticipants, no matter whether they were individuals affected
with cancer or their family members, were positive about
new genetic discoveries and genetic testing. Age and gender
were factors that influenced how people thought about gen-
etic discoveries and genetic testing. Although intention to
receive results may not translate into action, we believe that
if genetic testing for sarcoma becomes available in the fore-
seeable future, it is likely that family members may demon-
strate more reservation towards such testing than probands
and their spouses and this should be taken into consider-
ation. Finally, the majority of ISKS participants believe
people would like to be informed about incidental informa-
tion arising as a result of research.
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